Under the cooperative R&D agreement, the collaboration will leverage Calibrant’s unique proteomic technologies for the purposes of evaluating and validating protein markers for a variety of major, unmet medical needs.
Armed Forces Institute of Pathology’s (AFIP) tissue microarray laboratory will produce standard and custom tissue microarrays in agreement with Calibrant’s specifications. The initial project will be in the area of brain cancer, with the ultimate goal of identifying predictive markers for personalized medicine.
Michael Salgaller, COO of Calibrant, said: “Working in partnership with the AFIP via this cooperative R&D agreement, offers an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples.”